Evidence in Follow-up and Prognosis of Esophagogastric Junction Cancer

Publication date: Available online 20 September 2019Source: Cirugía Española (English Edition)Author(s): Lourdes Sanz Álvarez, Estrella Turienzo Santos, José Luis Rodicio Miravalles, María Moreno Gijón, Sonia Amoza Pais, Sandra Sanz Navarro, Amaya Rizzo RamosAbstractFive-year survival of tumors of the esophagogastric junction is 50%, in the most favorable stages and with the most effective adjuvant treatments. More than 40% of patients will have recurrences within a short period, usually the first year after potentially curative surgery. Survival after this recurrence is usually less than 6 months because treatment is not very effective, be it palliative chemotherapy, radiotherapy or surgical excision of single recurrences. As the detection of asymptomatic recurrences allows for earlier and more effective treatments to be used, the type and frequency of follow-up has an influence on survival.ResumenLa supervivencia a cinco años de los tumores de la unión esofagogástrica está en el 50% en los estadios más favorables y con los tratamientos coadyuvantes más eficaces. Más del 40% de los pacientes sufrirá recurrencias en un periodo breve, habitualmente en el primer año tras una cirugía potencialmente curativa y la supervivencia tras esa recurrencia suele ser menor de 6 meses, pues el tratamiento es poco eficaz, sea quimioterapia paliativa, radioterapia o exéresis ...
Source: Cirugia Espanola - Category: Surgery Source Type: research

Related Links:

Publication date: 19–25 October 2019Source: The Lancet, Volume 394, Issue 10207Author(s): Evelien Dekker, Pieter J Tanis, Jasper L A Vleugels, Pashtoon M Kasi, Michael B WallaceSummarySeveral decades ago, colorectal cancer was infrequently diagnosed. Nowadays, it is the world's fourth most deadly cancer with almost 900 000 deaths annually. Besides an ageing population and dietary habits of high-income countries, unfavourable risk factors such as obesity, lack of physical exercise, and smoking increase the risk of colorectal cancer. Advancements in pathophysiological understanding have increased the array of treatme...
Source: The Lancet - Category: General Medicine Source Type: research
ConclusionsBevacizumab was the only prescribed targeted therapy in first-line treatment. Considering the limited number of patients receiving first-line bevacizumab and the unknown reasons to prescribe additional targeted therapy, the corresponding survival rates of patients treated with and without additional bevacizumab in first-line treatment might suggest a limited clinical effect of bevacizumab in addition to first-line palliative chemotherapy on OS. Future research should focus on identifying the subgroup of patients who might benefit OR benefiting from anti-VEGF therapy in metastatic SBA.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research
Large cell neuroendocrine carcinoma (LCNEC) and small cell lung carcinoma (SCLC) are aggressive neuroendocrine tumors with poor survival rates [1 –3]. For stage IV SCLC, treatment has not advanced significantly over the last decades and consists of palliative chemotherapy. The same applies to stage IV LCNEC, were no standard treatment exists and palliative chemotherapy with SCLC and non-small cell lung cancer (NSCLC) regimens are both deeme d appropriate [4]. Recently, targeted therapy focusing on delta like protein 3 (DLL3) has received attention to improve outcomes for SCLC and LCNEC [5].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
CONCLUSION: Indian patients with colon cancer, at a tertiary referral center, tend to present at more advanced stages of the disease as compared to the West. However, curative treatment with surgery and chemotherapy offers similar survival outcomes when compared stage for stage.
Source: Indian Journal of Cancer - Category: Cancer & Oncology Authors: Source Type: research
Conclusion: Patients with advanced carcinoma GB were managed with various palliative procedures with the aim to improve the quality of life of patients because of jaundice, loss of appetite, nausea, pain, etc. Symptoms are distressing for patients.
Source: Indian Journal of Palliative Care - Category: Palliative Care Authors: Source Type: research
Conclusion: The incidence of bleomycin induced pulmonary toxicity and mortality was significantly higher in our study compared to that of other Western studies. This could be probably due to the increased susceptibility of the Indian patients to bleomycin induced lung damage. In a highly curable cancer such as HL, it is unacceptable to have such a high life-threating toxicity. Hence, an alternative chemotherapy regimen without bleomycin is to be explored which would prevent toxicity and hence the compromise on survival.
Source: Indian Journal of Palliative Care - Category: Palliative Care Authors: Source Type: research
Conclusion: The majority of our patients continue with anticancer treatments they possibly do not need and associated with poor survival.
Source: Indian Journal of Palliative Care - Category: Palliative Care Authors: Source Type: research
Publication date: Available online 8 October 2019Source: Social Science &MedicineAuthor(s): Rose-Anna Foley, Lucie Lechevalier Hurard, Annick Anchisi, Sandro AnchisiAbstractA new subfield of oncology has emerged in the last twenty years to raise awareness and address the specific needs of elderly cancer patients, a population that was long neglected in oncology. We sought to understand the individual experiences, as well as moral and social implications of considering elderly cancer patients as “treatable”.Following an anthropological critical interpretative approach focusing on practical and symbolic effec...
Source: Social Science and Medicine - Category: Psychiatry & Psychology Source Type: research
CONCLUSION: Although only 3 cases are reported, the exceptional results and the absence of side effects observed strongly warrant future trials to investigate the role intraperitoneal chemotherapy can have both as palliative treatment of refractory ascites and as salvage therapy in advanced endometrial cancer. PMID: 31597138 [PubMed - as supplied by publisher]
Source: Oncology - Category: Cancer & Oncology Authors: Tags: Oncology Source Type: research
by Drew Rosielle (@drosielle)A Series of Observations on Opioids By a Palliative Doc Who Prescribes A Lot of Opioids But Also Has Questions.This is the 5th post in a series about opioids, with a focus on how my thinking about opioids has changed over the years. See also:Part 1 – Introduction, General Disclaimers, Hand-Wringing, and a Hand-Crafted Graph.Part 2 – We Were Wrong 20 years Ago, Our Current Response to the Opioid Crisis is Wrong, But We Should Still Be Helping Most of our Long-Term Patients Reduce Their Opioid DosesPart 3 – Opioids Have Ceiling Effects, High-Doses are Rarely Therapeutic, and Ano...
Source: Pallimed: A Hospice and Palliative Medicine Blog - Category: Palliative Care Tags: cancer opioids pain rosielle The profession Source Type: blogs
More News: Cancer | Cancer & Oncology | Chemotherapy | Men | Palliative | Surgery